* To replay the media content and watch again, please refresh your screen

In this interactive patient case video, you'll meet a 62-year-old man with advanced renal cell carcinoma (RCC) and follow his journey through selection of 1st- and 2nd-line therapies and managing associated toxicities. Along the way, you'll answer questions at key points, and engage with clickable resources to deepen your understanding of:

  • The different efficacy and safety profiles of targeted and immunotherapy treatments for RCC
  • How to implement targeted therapies and immunotherapies into treatment strategies for advanced RCC
  • Optimal sequencing of treatments
  • The cause of toxicities and strategies to improve tolerability and manage side effects whilst maintaining optimal efficacy

 

Clinical Takeaways

  • Current clinical practice for patients with advanced ccRCC is frontline combination of immunotherapy-VEGFR TKI for IMDC intermediate/poor-risk patients

  • Adverse events can generally be managed through dosing strategies, enabling the patient to remain on first-line therapy as long as possible

  • Switching to 2nd-line therapy should ideally be at the point of disease progression

Viktor Grünwald is a professor for Interdisciplinary Genitourinary Oncology at the University Hospital Essen in Essen, Germany. Professor Grünwald specialises in Internal Medicine and Medical Oncology. His main areas of research interest are in GU cancers, soft tissue sarcomas, head and neck cancers, with an emphasis on the academic development and translational research of immunotherapies in these indications.

Professor Grünwald graduated from the Medical School Hannover in 1998, after which he was appointed as a Private Lecturer and later professor for Haematology and Oncology at the same institution. He became professor for Interdisciplinary Genitourinary Oncology at the University Hospital Essen in 2018, thereby chairing the section for medical treatments of GU cancers.

Professor Grünwald served at the steering committee for genitourinary (GU) cancers (non-prostate) at the ESMO and ESMO ASIA Congress and was part of scientific committees of the International Kidney Cancer Symposium (EIKCS), German Cancer Congress (DKK) and the German Society for Haematology and Oncology (DGHO). He has chaired different working groups in academic organizations, such as the Central European Society of Anticancer Drug Research (CESAR) studies group, German Medical Oncology studies group (AIO) and German Cancer Society (DKG). His training activities include ESMO preceptorships and the ECCO-AACR-EORTC-ESMO workshop on methods in clinical cancer research (MCCR).

Prof. Viktor Grünwald has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, AstraZeneca, Astellas, BMS, Debiopharm, Gilead, Eisai, Ipsen, Johnson & Johnson, Merck, MSD, Novartis/AAA, Oncorena, Pfizer, Telix Pharmaceutical, Recordati, Roche and Synthekine. 

Programme summary
  • clock Duration 15 MIN
  • clock Language(s) flag
Share this programme
This educational programme is supported by an Independent Educational Grant from Eisai Europe Limited.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Eisai Europe Limited.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update
Oncology 
Coming soon! Highlights from ESMO 2025

Experts are joining us at ESMO 2025 to share their views on new data on GU, lung, breast, gynecological and upper GI cancers

Experts
Dr Herbert H. Loong, Prof. Viktor Grünwald, Prof. Thomas Powles, Dr Elisa Agostinetto, Prof. Nicoletta Colombo, Dr Elizabeth Smyth
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • clock MIN
  • calendar Oct 2025
  • Non-accredited Independent Medical Education

NSCLC and RCC updates supported by Independent Education Grants from Bayer and Eisai Europe Ltd. respectively. All other updates supported by COR2ED.
podcast Video podcast
Oncology Endocrinology Rare diseases 
Exploring the role of targeted radiopharmaceutical treatment in NETs

PRRT and emerging strategies in neuroendocrine tumours

Experts
Prof. Ken Herrmann, Dr Heloisa Soares, Oncology Brothers (Moderators)
Endorsed by
NANETS
CommNETs Neuroendocrine Cancer UK
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar Oct 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from ITM.
ipcv Interactive Patient Case Video (IPCV)
Oncology 
Shared decision-making for prostate cancer patients

Early treatment intensification with a PARPi plus ARPI combination

Experts
Prof. Gunhild von Amsberg
Endorsed by
ZERO Urobel VZW | ASBL
EAUN
  • clock 25 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca 
conference-update Conference update
Oncology 
Oncogene-addicted NSCLC highlights from WCLC 2025

Expert insights on the latest data in oncogene-addicted non-small cell lung cancer 

Experts
Dr Devika Das
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
Lung Cancer Research Foundation
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Video podcast
Oncology 
Understanding the BRAFV600E testing and treatment landscapes in NSCLC

Two perspectives, one aim: A pathologist and a medical oncologist in discussion

Experts
Assoc. Prof. Umberto Malapelle, Prof. Nicolas Girard
Endorsed by
ISLB
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.